Study guide

12.3 Breast Masses, Thyroid Nodule Evaluation & Surgical Oncology

Saudi Medical Licensing Examination SMLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & Foundation of Clinical Practice

1.1 Exam Format, Blueprint & Preparation Strategy 1.2 Medical Bioethics, Patient Safety & SCFHS Regulations 1.3 Biostatistics & Clinical Epidemiology in Saudi Healthcare

2 Chapter 2: Internal Medicine - Cardiovascular & Respiratory Systems

2.1 Coronary Artery Disease, Dysrhythmias & Heart Failure 2.2 Respiratory Failure, Asthma, COPD & Infiltrative Lung Diseases 2.3 Critical Care Medicine, Shock Syndromes & Mechanical Ventilation

3 Chapter 3: Internal Medicine - Gastroenterology, Renal & Endocrine Systems

3.1 Hepatobiliary Disorders, Peptic Ulcers & Inflammatory Bowel Disease 3.2 Acute Kidney Injury, Chronic Kidney Disease & Electrolyte Imbalances 3.3 Diabetes Mellitus, Thyroid Disorders & Adrenal Axis Pathologies

4 Chapter 4: Internal Medicine - Infectious Diseases, Hematology & Subspecialties

4.1 Saudi Regional Infections (MERS-CoV, Brucellosis, TB, Dengue) & Antimicrobial Therapy 4.2 Hemoglobinopathies (Sickle Cell & Thalassemia), Anemias & Hematologic Malignancies 4.3 Connective Tissue Diseases, Stroke, Epilepsy & Movement Disorders 4.4 Psychiatry, Geriatrics & Behavioral Health

5 Chapter 5: Obstetrics - Antepartum & Intrapartum Care

5.1 Routine Prenatal Care, Screening & Fetal Assessment 5.2 Placental Disorders, Bleeding in Pregnancy & Isoimmunization 5.3 Normal Labor, Malpresentation, Operative Delivery & Fetal Monitoring

6 Chapter 6: Obstetrics - High-Risk Complications & Postpartum Care

6.1 Preeclampsia, Eclampsia & HELLP Syndrome 6.2 Preterm Labor, Premature Rupture of Membranes & Cervical Insufficiency 6.3 Postpartum Hemorrhage, Puerperal Infections & Maternal Mortality

7 Chapter 7: Gynecology & Reproductive Health

7.1 Menstrual Disorders, Endometriosis & Fibroids 7.2 Infertility Workup, Contraception & Menopause 7.3 Cervical, Uterine & Ovarian Neoplasms

8 Chapter 8: General Pediatrics, Neonatology & Development

8.1 Developmental Milestones, Growth Charts & Failure to Thrive 8.2 Saudi National Immunization Schedule & Well-Child Care 8.3 Neonatal Resuscitation, Jaundice, Respiratory Distress & Prematurity

9 Chapter 9: Pediatric Medicine - Respiratory, Cardiac & GI

9.1 Croup, Epiglottitis, Bronchiolitis, Asthma & Cystic Fibrosis 9.2 Congenital Heart Disease (Cyanotic & Acyanotic) & Rheumatic Fever 9.3 Dehydration, Gastroenteritis, Intussusception & Pyloric Stenosis

10 Chapter 10: Pediatric Medicine - Infections, Hematology, Emergencies & Subspecialty Systems

10.1 Exanthems, Meningitis, Sepsis & Febrile Seizures 10.2 Pediatric Sickle Cell Vaso-occlusive Crises, Thalassemia & ITP 10.3 Pediatric Trauma, Ingestion, Poisoning & Child Abuse Recognition 10.4 Pediatric Neurology, Nephrology & Musculoskeletal Disorders

11 Chapter 11: General Surgery & Surgical Principles

11.1 Preoperative Risk Assessment, Wound Healing & Surgical Infections 11.2 Fluid Resuscitation, Acid-Base Disturbances & Surgical Shock 11.3 Acute Abdomen, Appendicitis, Hernias, Gallbladder & Colorectal Surgery

12 Chapter 12: Trauma, Critical Care & Surgical Emergencies

12.1 ATLS Primary/Secondary Survey, Thoracic & Abdominal Trauma 12.2 Thermal/Chemical Burns, Parkland Formula & Wound Management 12.3 Breast Masses, Thyroid Nodule Evaluation & Surgical Oncology

13 Chapter 13: Surgical Subspecialties

13.1 Nephrolithiasis, BPH, Prostate Cancer & Increased Intracranial Pressure 13.2 Common Fractures, Compartment Syndrome & Pediatric Orthopedics 13.3 Epistaxis, Red Eye Emergencies, Peripheral Vascular Disease & Aortic Aneurysms

12.3 Breast Masses, Thyroid Nodule Evaluation & Surgical Oncology

Key Takeaways Explain This Topic AI

The triple assessment for any breast mass consists of clinical examination, radiological imaging (mammography/ultrasound), and pathological tissue sampling (core needle biopsy).

The BI-RADS classification guides breast imaging management: BI-RADS 4 or 5 indicates a suspicious or highly suggestive malignancy, mandating a tissue biopsy.

A palpable breast mass in a woman under 30 is typically evaluated initially with an ultrasound, whereas a mammogram is the primary imaging modality for women over 40.

The initial evaluation of a thyroid nodule includes a serum TSH and a dedicated neck ultrasound.

The Bethesda System for Reporting Thyroid Cytopathology guides management following fine-needle aspiration (FNA); a Bethesda VI result (malignant) typically requires total thyroidectomy.

Last updated: July 2026

Surgical Oncology: Breast Cancer & Thyroid Nodule Algorithms

Surgical oncology forms a critical component of General Surgery on the SMLE (~15% of total exam). Breast cancer is the most common female malignancy in Saudi Arabia (representing >30% of all female cancers in KSA). Mastery of the Triple Assessment, age-stratified diagnostic imaging algorithms, BI-RADS management categories, breast cancer staging and surgical options, as well as TSH-guided thyroid nodule evaluation and Bethesda cytological reporting, is mandatory.

Evaluation of a Palpable Breast Mass: The Triple Assessment

Any palpable breast mass or suspicious screening mammogram requires systematic evaluation via the Triple Assessment . The diagnostic concordance of all three modalities approaches 100% sensitivity:

Clinical Assessment: Meticulous clinical history (family history, BRCA status, nulliparity, age at menarche/menopause, hormone replacement therapy) and bilateral Clinical Breast Examination (CBE) evaluating mass mobility, skin tethering, nipple retraction/discharge, and axillary lymphadenopathy.

Radiological Imaging: Age-stratified imaging (Ultrasound vs. Mammography).

Pathological Confirmation: Core Needle Biopsy (CNB) under imaging guidance.

Age-Stratified Radiological Workup

Women < 30 Years Old: Initial imaging of choice is Targeted Breast Ultrasound . Younger women possess dense fibroglandular breast tissue that significantly attenuates X-rays, reducing mammographic sensitivity. Ultrasound accurately differentiates fluid-filled simple cysts (benign) from solid masses (fibroadenoma vs. carcinoma).

Women ≥ 40 Years Old: Initial imaging of choice is Diagnostic Bilateral Mammography plus targeted breast ultrasound. Mammography detects non-palpable microcalcifications (pleomorphic, linear branching)—the hallmark of early ductal carcinoma in situ (DCIS)—and architecture distortion.

Women Aged 30 to 39 Years: Diagnostic ultrasound is performed first; mammography is added if sonographic features are suspicious or indeterminate.

Breast Imaging Reporting and Data System (BI-RADS)

BI-RADS standardizes mammographic and sonographic findings, stratifies risk of malignancy, and dictates clinical action:

BI-RADS Category Assessment Classification Malignancy Risk (%) Required Clinical Action

BI-RADS 0 Incomplete Evaluation N/A Obtain additional imaging views or compare with prior films.

BI-RADS 1 Negative (Normal) 0% Routine age-appropriate screening.

BI-RADS 2 Benign Finding (e.g., simple cyst, fibroadenoma) 0% Routine age-appropriate screening.

BI-RADS 3 Probably Benign Finding ≤ 2% Short-interval follow-up (repeat ultrasound/mammogram in 6 months) .

BI-RADS 4 Suspicious Abnormality (4a: 2-10%, 4b: 10-50%, 4c: 50-95%) 2% to 94% Core Needle Biopsy (CNB) Mandatory .

BI-RADS 5 Highly Suggestive of Malignancy ≥ 95% Core Needle Biopsy (CNB) Mandatory .

BI-RADS 6 Known Biopsy-Proven Malignancy 100% Surgical excision & multidisciplinary oncologic treatment plan.

Biopsy Technique Standards

Core Needle Biopsy (CNB): The GOLD STANDARD for evaluating solid breast masses. Unlike Fine-Needle Aspiration (FNA), CNB yields a tissue core preserving histologic architecture . This allows pathologists to distinguish non-invasive (in situ) from invasive carcinoma (ductal vs. lobular) and test for biomarker expression ( ER, PR, HER2/neu status).

Fine-Needle Aspiration (FNA): Limited to therapeutic aspiration of painful simple cysts or cytological staging of palpable axillary lymph nodes. FNA CANNOT differentiate DCIS from invasive ductal carcinoma.

Surgical Management of Breast Cancer

Breast-Conserving Surgery (BCS / Lumpectomy) + Radiation: Equivalent long-term overall survival compared to total mastectomy for early-stage disease (Stage I & II). Requires negative surgical margins.

Axillary Staging: Sentinel Lymph Node Biopsy (SLNB) is standard of care for clinically node-negative (cN0) patients to avoid axillary lymph node dissection (ALND) morbidity (lymphedema). If SLNB is positive for macrometastases, further management (radiation vs. ALND) is evaluated.

Neoadjuvant Systemic Therapy: Preferred for Locally Advanced Breast Cancer (LABC - Stage III) or Triple-Negative / HER2-positive tumors to downstage the tumor prior to surgery.

Diagnostic Workup of a Thyroid Nodule

Thyroid nodules are present in 5-10% of adults. Evaluation aims to identify the ~5% of nodules that represent thyroid carcinoma (Papillary, Follicular, Medullary, Anaplastic).

Stepwise Diagnostic Algorithm

Step 1: Serum TSH Level (Priority Laboratory Test):

If TSH is LOW (Suppressed): Indicates hyperthyroidism. Order a Radionuclide Thyroid Scan (Iodine-123 or Tc-99m) :

"Hot" (Hyperfunctioning) Nodule: Takes up radioisotope preferentially. Malignancy risk is <1%. Biopsy is NOT indicated. Treat hyperthyroidism.

"Cold" (Non-functioning) Nodule: Fails to take up isotope. Malignancy risk ~15%. Proceed to ultrasound.

If TSH is NORMAL or HIGH: Malignancy risk is higher. Proceed directly to Dedicated Neck Ultrasound .

Step 2: High-Resolution Thyroid Ultrasound:

Identifies high-risk sonographic features: Solid composition, hypoechogenicity , microcalcifications , irregular/microlobulated margins , taller-than-wide shape , and extrathyroidal extension.

Step 3: Fine-Needle Aspiration (FNA) Cytology:

Performed under ultrasound guidance for nodules ≥1.0 cm with high-risk features, or ≥1.5-2.0 cm with moderate/low-risk features.

Cytological Reporting: The Bethesda System for Reporting Thyroid Cytopathology

Bethesda Category Diagnostic Diagnosis Malignancy Risk Standard Surgical / Clinical Management

Bethesda I Non-diagnostic / Unsatisfactory 5-10% Repeat ultrasound-guided FNA.

Bethesda II Benign (Colloid nodule, Hashimoto's) 0-3% Clinical and sonographic surveillance.

Bethesda III Atypia / Follicular Lesion of Undetermined Significance (AUS/FLUS) 10-30% Repeat FNA or molecular marker testing.

Bethesda IV Follicular Neoplasm / Suspicious for Follicular Neoplasm 25-40% Diagnostic Hemithyroidectomy / Lobectomy . (Cannot distinguish Follicular Adenoma from Carcinoma on FNA!).

Bethesda V Suspicious for Malignancy 50-75% Near-Total / Total Thyroidectomy or Lobectomy.

Bethesda VI Malignant (Papillary, Medullary, Anaplastic) 97-99% Total Thyroidectomy + central lymph node dissection if indicated.

Critical Pathological Distinction: Papillary Thyroid Carcinoma presents with characteristic nuclear features ( Orphan Annie eyes nuclei , psammoma bodies, nuclear grooves) and can be diagnosed by FNA. In contrast, Follicular Carcinoma CANNOT be diagnosed by FNA because cytology cannot evaluate for capsular or vascular invasion , which defines malignancy versus benign follicular adenoma. Therefore, Bethesda IV lesions mandate surgical lobectomy for histological confirmation.